Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes

 Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for
                 Optimal Care for Young People with Diabetes

PR Newswire

PARIS and BOSTON, Nov. 14, 2012

PARIS and BOSTON, Nov. 14, 2012 /PRNewswire/ --Sanofi (EURONEXT: SAN and
NYSE: SNY) and T1D Exchange, a non-profit organization focused on type 1
diabetes, announced today on World Diabetes Day that they will collaborate on
the TEENs registry study. The aim of the study is to provide the type 1
diabetes community with a better understanding of how children, adolescents
and young adults are currently living with type 1 diabetes, and to deliver
recommendations for better disease management and patients outcomes.

(Logo: http://photos.prnewswire.com/prnh/20121114/NY12338LOGO)
(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO )

TEENs, also known as the "Glycemic control and quality of life in children,
adolescents, and young adults with type 1 diabetes mellitus described in a
worldwide, cross-sectional study in 2012," is a multinational, observational,
cross-sectional study that will evaluate the percentage of type 1 diabetes
patients between the ages of 8 and 25 with controlled glycemia, as measured by
hemoglobin A1c (HbA1c). Secondary outcomes will include measurements of
quality of life and emotional status, the relationship between glycemic
control and quality of life, and the impact of factors such as medical care on
these two measurements.

"To better understand how to treat young people with type 1 diabetes, we need
to know how exactly they are living with the disease. Our goal with the TEENs
study is to examine how clinical factors such as glycemic control impact the
quality of life of this particularly vulnerable group of young people with
diabetes," said Riccardo Perfetti, MD, Vice President Medical Affairs, Global
Diabetes, Sanofi. "TEENs is another example of Sanofi's ongoing commitment to
further develop the understanding of optimal type 1 diabetes care."

The TEENs study will enroll more than 7,000 people with type 1 diabetes in 20
countries, with a sample representative of the typical medical care in the
respective country. In the US, Sanofi works in partnership with T1D Exchange
for the recruitment of the young study participants and for implementation of
this study. Worldwide, Sanofi partners with various clinic centers, hospitals,
and healthcare professionals.

"We are excited to support Sanofi and the TEENs study with T1D Exchange's
patient registry and extensive clinic network in the US. We are also honored
to be designated by Sanofi as a clinical trial Center of Excellence," said
Dana Ball, CEO and Cofounder of the T1D Exchange. "This collaboration
demonstrates the unique efficiencies and capabilities that partnerships with
foundation-driven clinical exchanges can create."

Data will be collected from healthcare professionals, parents or guardians,
and patients. Anticipated outcomes include: identification of predictive
factors for glucose control and acute complications of type 1 diabetes, better
understanding of unmet needs of young people with type 1 diabetes in different
age groups, documentation of insulin regimens in young people with type 1
diabetes, and description of the patient journey from pediatric to adult care
services.

Results from the TEENs study will be presented at scientific congresses in
2013 and in 2014.

About Diabetes
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an
autoimmune disease characterized by the lack of insulin (the hormone that
regulates blood glucose concentrations) production by the pancreas, and type
2, a metabolic disorder in which there are two main biological defects: a
deficient production of insulin and reduced ability of the body to respond to
the insulin being produced. Type 1 and type 2 diabetes are characterized by an
increase in blood glucose concentrations (hyperglycemia). Over time,
uncontrolled hyperglycemia leads to the macrovascular and microvascular
complications of diabetes. Macrovascular complications, which affect the large
blood vessels, include heart attack, stroke and peripheral vascular disease.
Microvascular complications affect the small blood vessels of the eyes
(retinopathy), kidney (nephropathy) and nerves (neuropathy). More than 18
million people worldwide are living with type 1 diabetes. And, the incidence
of type 2 diabetes is growing at an alarming rate, with nearly 348 million
people worldwide living with the condition today.

About T1D Exchange
T1D Exchange is a non-profit organization with the mission to improve outcomes
of people touched by type 1 diabetes by accelerating the discovery of new
approaches to research and development. It connects the disparate stakeholders
in the type 1 diabetes community by combining the critical components of
traditional clinical research with the expanding fields of health information
technology and social networking.

T1D Exchange evolved as a solution to mitigate barriers and inefficiencies for
type 1 diabetes research and development. It is a personalized exploration
platform anchored in health informatics: T1D Exchange consists of Glu, an
interactive website with mobile capabilities for patients and caregivers; a
network of 69 clinics across the United States; and a biorepository comprising
clinically annotated patient biological samples. T1D Exchange was founded in
2011 through a grant from The Leona M. and Harry B. Helmsley Charitable Trust.
More information is available at www.t1dexchange.org.

About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including innovative blood glucose monitoring
systems. Sanofi markets both injectable and oral medications for people with
type 1 or type 2 diabetes. Investigational compounds in the pipeline include
an injectable GLP-1 receptor agonist being studied as a single agent, in
combination with basal insulin, and/or in combination with oral anti-diabetic
agents.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.



Contacts:
Sanofi                              T1D Exchange
Corporate Media Relations           Ellen Giller
Marisol Peron                       Tel: + 1 (617) 892-6132
Tel: +33 1 53 77 45 02              E-mail: egiller@t1dexchange.org
Mobile: +33 6 08 18 94 78
E-mail: mr@sanofi.com
Global Diabetes Division Communications
Tilmann Kiessling
Mobile: +49 172 61 59 291
E-mail: TilmannKiessling@sanofi.com
US Diabetes Communications
Susan Brooks
Tel: +1(908) 981-6566
Mobile: +1 (201) 572-4994
E-mail: Susan.Brooks@sanofi.com 



SOURCE Sanofi

Website: http://www.t1dexchange.org
 
Press spacebar to pause and continue. Press esc to stop.